Pharmaceutical - Novo Nordisk

Filter

Current filters:

Novo Nordisk

Popular Filters

1 to 25 of 135 results

Positive new Ph III data with Novo Nordisk’s Xultophy

Positive new Ph III data with Novo Nordisk’s Xultophy

11-08-2014

Positive new pivotal Phase III data about Xultophy (insulin degludec/liraglutide), formerly known as…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchXultophy

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

Added benefit of Novo Nordisk’s Tresiba not proven, says IQWiG

08-08-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

DiabetesGerman Institute for Quality and EfficiencyGermanyNovo NordiskPharmaceuticalPricingRegulationTresiba

Novo Nordisk beats estimates as net profit grows 4%

Novo Nordisk beats estimates as net profit grows 4%

07-08-2014

Danish diabetes care giant Novo Nordisk released first-half 2014 financial results this morning, showing…

Business FinanceChief executiveDiabetesFinancialNOKNovo NordiskPeptide hormonesPharmaceuticalRecombinant proteins

Existing diabetes drug Victoza could be effective treatment for world’s obese

Existing diabetes drug Victoza could be effective treatment for world’s obese

06-08-2014

Pharmaceutical companies are racing to find a new form of obesity drug as patient numbers spiral and…

Anti-diabetic drugsDiabetesGastro-intestinalsGlobalMarkets & MarketingNovo NordiskPeptide hormonesPharmaceuticalVictoza

Global insulin market set to reach $32.24 billion in 2019

Global insulin market set to reach $32.24 billion in 2019

28-07-2014

The global insulin market was valued at $19.99 billion in 2012 and is expected to expand at a compound…

AfrezzaChinaDiabetesEli LillyGlobalInsulinLY2605541MannKindMarkets & MarketingMerck & CoMK-1293NN1218Novo NordiskPharmaceutical

Novo Nordisk gains FDA backing for new NovoSeven RT indication

Novo Nordisk gains FDA backing for new NovoSeven RT indication

09-07-2014

Danish diabetes care giant Novo Nordisk’s hemophilia treatment NovoSeven RT (coagulation factor VIIa…

HematologyNovo NordiskNovoSevenNovoSeven RTPharmaceuticalRare diseasesRegulationUSA

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

Glowing prospects for Novo Nordisk's insulin degludec/liraglutide for type 2 diabetes

07-07-2014

Danish diabetes care giant Novo Nordisk's fixed-dose combination therapy insulin degludec/liraglutide…

DiabetesEuropeIDegLiraMarkets & MarketingNovo NordiskPharmaceuticalUSAXultophy

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

Positive new Ph IIIa data on Novo Nordisk’s liraglutide

23-06-2014

New data for Danish diabetes care giant Novo Nordisk’s liraglutide 3mg from the Phase IIIa SCALET Obesity…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

Novo Nordisk launch new insulin device Levemir FlexTouch in USA

19-06-2014

Danish diabetes care giant Novo Nordisk has launched its newest prefilled insulin delivery device Levemir…

DiabetesLevemirMarkets & MarketingNovo NordiskPharmaceuticalUSA

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

ADA 2014: New data on Novo Nordisk’s IDegLira and Victoza

15-06-2014

A new Phase IIIa study shows that IDegLira, the once-daily single injection combination of Danish diabetes…

DiabetesIDegLiraNovo NordiskPharmaceuticalResearchVictoza

6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark

6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark

11-06-2014

Up to 2022, Danish diabetes care giant Novo Nordisk expects to hire 6,000 new employees in Denmark, half…

BoardroomDenmarkDiabetesManagementNovo NordiskPharmaceutical

Quebec first province to add Victoza to the drug benefit formulary

Quebec first province to add Victoza to the drug benefit formulary

04-06-2014

The Canadian subsidiary of Danish diabetes care giant Novo Nordisk says that the Quebec government has…

CanadaDiabetesFinancialHealthcareNovo NordiskPharmaceuticalVictoza

Significantly greater weight loss versus placebo seen in Ph IIIa study of liraglutide 3mg

16-05-2014

Significant weight loss was demonstrated for Danish insulin giant Novo Nordisk’s diabetes drug liraglutide…

DiabetesliraglutideMetabolicsNovo NordiskPharmaceuticalResearch

Preventative treatment with NovoEight reduces bleeding in hemophilia A

Preventative treatment with NovoEight reduces bleeding in hemophilia A

12-05-2014

Danish insulin giant Novo Nordisk has announced new Phase III interim data from its guardianT2 trial…

Coagulation systemDenmarkGuardianT2HematologyInsulin giantNovo NordiskNovoEightPharmaceuticalResearchVIII (rFVIII)World Congress

Healthy 1st-qtr growth reported Novo Nordisk, which beats forecasts

Healthy 1st-qtr growth reported Novo Nordisk, which beats forecasts

01-05-2014

Danish diabetes care giant Novo Nordisk increased operating profit in local currencies by 15% in the…

DiabetesNovo NordiskPharmaceutical

IQWiG finds added benefit for Novo Nordisk’s NovoEight not proven

23-04-2014

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

GermanyHematologyNorthern EuropeNovo NordiskNovoEightPharmaceuticalPricingRegulation

Label updates for Tresiba and Victoza backed by EMA committee

21-03-2014

The European Medicines agency’s Committee for Medicinal Products for Human Use has issued positive…

DiabetesEuropeNovo NordiskPharmaceuticalRegulationTresibaVictoza

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

Positive Ph III results with Novo Nordisk’s N8-GP, a long-acting hemophilia A agent

19-03-2014

Danish insulin giant Novo Nordisk says it has completed the pathfinderT2, the first Phase III trial with…

HematologyN8-GPNovo NordiskPharmaceuticalResearchturoctocog alfa

Novo Nordisk invests $100 million in new purification pilot plant in Denmark

Novo Nordisk invests $100 million in new purification pilot plant in Denmark

14-03-2014

Danish insulin giant Novo Nordisk revealed this morning that it is increasing its drug development capacity…

DiabetesFinancialNovo NordiskPharmaceuticalProduction

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

Novo Nordisk’s novel therapy could offer better outcomes for type 2 diabetes patients

05-03-2014

Danish insulin giant Novo Nordisk has presented positive data at the Diabetes UK conference from its…

DenmarkDiabetesIDegLiraNovo NordiskPharmaceuticalResearchUK

India’s patents moves could see particular uncertainty for diabetes sector

India’s patents moves could see particular uncertainty for diabetes sector

17-02-2014

The Indian government's decision to review patented drugs by multinationals, to allow for the manufacture…

Abbott LaboratoriesAsia-PacificDiabetesEli LillyIndiaMarkets & MarketingMerck & CoNovo NordiskPatentsPharmaceutical

Five big pharma firms named as high performers in annual biopharmaceutical report

Five big pharma firms named as high performers in annual biopharmaceutical report

12-02-2014

Entry in emerging markets and expedient product launches are still driving the pharma market, according…

AmgenAstellas PharmaBristol-Myers SquibbFinancialMarkets & MarketingNovo NordiskPharmaceuticalResearchRoche

1 to 25 of 135 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top